PENSACOLA, FL, October 30, 2024 - ActiGraph, a leading provider of wearable technology and scientific services for clinical drug development and academic research, announced a new strategic partnership with Indivi, a TechBio company transforming smartphones into precision medicine tools for neuroscience research and development.
Indivi’s best-in-class digital measurement technology solution brings together KonectomTM (licensed from Biogen) and dreaMSMD technologies to capture disability concepts of interest that are key to understanding neurodegenerative diseases. Indivi is developing and validating smartphone sensor-derived measures of motor functions, cognition, vision and voice to de-risk drug development in neuroscience through more comprehensive and precise functional endpoints.
ActiGraph’s AccelerantTM partnership program is designed to advance the use of digital health technologies (DHTs) in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams. This strategic partnership enables researchers to gain a more precise understanding of patient functioning by capturing key patient-centric, low burden measures in clinical trials of Parkinson’s disease, Multiple Sclerosis, Alzheimer’s disease, and related dementias.
"The industry does not have the right measurement tools to succeed in many neurology clinical trials," said Christine Guo, Chief Scientific Officer at ActiGraph and a neuroscientist by training. “Neurodegenerative diseases have heterogenous and multifaceted clinical presentations and can progress very slowly. So, to detect the potential treatment effects in a clinical trial, we need measurement tools with high precision that can tell the true signals from the noise. We’re excited to partner with Indivi to offer a comprehensive suite of digital measures, providing our biopharma partners with the right tools to tackle these challenging diseases.”
"The phase 2 proof-of-concept demonstration of a modest treatment effect in slowing the course of disability accumulation is where neuroscience drug development generally fails, as the putative signal remains buried in the measurement noise," said Shibeshih Belachew, Chief Medical Officer at Indivi, neurologist, and drug developer. "We aim to transform drug development in an area where current phase 2 proof-of-concept studies may only have a decent chance of success if designed with the size and duration of a phase 3. This is prohibitive and hampers competitive investments in a field of devastating and hard-to-treat neurological diseases compared to other less challenging therapeutic areas, which are easier to measure. You cannot treat what you cannot measure, and we are thrilled to join forces with ActiGraph as we’ll be so much stronger together, to make measurable what is not so."
About ActiGraph
ActiGraph is pioneering the digital transformation of clinical research. We provide end-to-end digital health technology (DHT) solutions by integrating and operationalizing the best hardware, software, and algorithms to generate reliable evidence and get the right treatments to the right patients, faster. ActiGraph’s medical-grade wearable technology platform has been used to capture real-world, continuous digital measures of activity, sleep, and mobility for nearly 250 industry-sponsored clinical trials and thousands of academic research studies. Appearing in over 25,000 published scientific papers to date, ActiGraph is the most experienced and trusted wearable technology partner in the industry.
About Indivi
Indivi is a TechBio company developing functional biomarkers as drug development tools for neurological diseases in the form of sensor-derived measurements generated from smartphone-based assessments of cognition, motion, vision and voice.
Indivis committed to developing future-proof and transformative digital endpoints as deep phenotyping instruments to accelerate and de-risk drug development in neurodegenerative disorders such as Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and related dementias. Indivi is nurturing a unique symbiotic intersection between expert in-house knowledge and experience in data science, clinical development, signal processing engineering, and advanced analytics including computational intelligence. Through end-to-end joint endeavors with biopharmaceutical companies, Indivi is poised to continue its growth in the nascent digital endpoint industry to improve the probability of technical and regulatory success in neuroscience drug development.
